PRESENTATION · Dec 2023 · PDF

Infigratinib - ENDO 2023 - PROPEL, PROPEL 2 and PROPEL OLE

PRESENTATION · Dec 2023 · PDF

Encaleret - ADH1 - ESE 2023 12 Month Phase 2b Data

PRESENTATION · Dec 2023 · PDF

Infigratinib - ENDO 2023 -Evaluation of Bone Mineral Density

PRESENTATION · Dec 2023 · PDF

infigratinib - PROPEL2 Topline Results

PUBLICATION · Sep 2023

The New England Journal of Medicine, Efficacy and Safety of Encaleret in Autosomal Dominant Hypocalcemia Type 1

PRESENTATION · Dec 2022 · PDF

BBIO--CAH-GTx-BBP-631--ENDO-2022--Pre-screening-Protocol

PUBLICATION · Dec 2022 · PDF

PLOS One, Ribitol Dose-dependently Enhances Matriglycan Expression and Improves Muscle Function with Prolonged Life Span in Limb-girdle Muscular Dystrophy 2I/R9 Mouse Model

PUBLICATION · Oct 2022 · PDF

Journal of Bone and Mineral Research, Autosomal Dominant Hypocalcemia Type 1: A Systematic Review

PUBLICATION · Mar 2022 · PDF

Nature Reviews: Endocrinology, International Consensus Statement on the Diagnosis, Multidisciplinary Management and Lifelong Care of Individuals with Achondroplasia

PUBLICATION · Feb 2022 · PDF

Therapeutic Advances in Muscoskeletal Disease, Infigratinib in Children with Achondroplasia: The PROPEL and PROPEL 2 Studies